Retrospective Review of Dual CGRP-Targeted Regimens for Acute and Preventive Treatment of Migraines in a Veteran Population.

A recent study examined the safety and effectiveness of dual CGRP-targeted treatments for migraines. Researchers focused on patients who used both preventive and acute CGRP medications. The study included 89 participants, mostly women, with an average age of 46.8 years. These patients had chronic migraines and received treatment between April 2023 and January 2025. There has been some debate about using these medications together. The study aimed to provide more clarity on this issue. It analyzed prescription records from electronic health records. The primary goal was to evaluate safety, while a secondary goal explored how well these treatments worked together. Results showed that using both types of CGRP-targeted therapies might be safe for patients. However, more research is needed to confirm these findings and understand the best treatment strategies for migraine patients. Clinical relevance: This study suggests that using dual CGRP-targeted therapies may be safe, potentially improving treatment options for patients with chronic migraines.